Adipotide (FTPP): Complete Research Profile — Prohibitin-Targeting Proapoptotic Peptide for Adipose Vasculature Research

Adipotide (FTPP): Complete Research Profile — Prohibitin-Targeting Proapoptotic Peptide for Adipose Vasculature Research

Adipotide — formally termed FTPP (Fat-Targeting Proapoptotic Peptide) or prohibitin-targeting peptide 1 — is a bipartite peptidomimetic designed to selectively induce apoptosis in the endothelium of white adipose tissue (WAT) vasculature. Unlike systemic metabolic interventions, adipotide operates through vascular-targeted cell killing: a homing peptide guides the construct to adipose blood vessels, where a proapoptotic effector domain disrupts mitochondrial membrane integrity and triggers programmed cell death. The resulting selective devascularization of white fat depots produces adipocyte necrosis and fat mass reduction in preclinical models — with no reported toxicity in normal-weight animals, underscoring the tissue-selectivity of the mechanism.

This profile is provided for Research Use Only (RUO). Adipotide is an experimental research compound. All content is educational.

---

Quick Reference

---

Molecular Architecture: A Bipartite Design

Adipotide consists of two functional domains covalently joined by a diglycine (GG) linker:

1. Targeting Domain (CKGGRAKDC): This nonapeptide homing sequence was identified through in vivo phage display screening of peptides that home specifically to white adipose tissue vasculature. It binds prohibitin (PHB), a multifunctional protein expressed on the inner luminal surface of adipose endothelium but not on blood vessels of most other normal tissues. This differential prohibitin surface expression provides the spatial selectivity of the whole construct.

2. Proapoptotic Effector Domain (D[KLAKLAK]₂): The D-amino acid version of the amphipathic peptide (KLAKLAK)₂, a cationic sequence that inserts into and disrupts phospholipid bilayers of mitochondrial membranes upon cell internalization. D-amino acid substitution confers resistance to proteolytic degradation in biological matrices. Upon entry into prohibitin-expressing endothelial cells, D(KLAKLAK)₂ rapidly permeabilizes mitochondrial outer membranes, triggering cytochrome c release and downstream caspase cascade activation — irreversible apoptosis.

Full sequence: CKGGRAKDC-GG-D(KLAKLAK)₂

Approximate molecular weight: ~2,800 Da

Synthesis complexity: Moderate-high; requires D-amino acid incorporation and disulfide bond formation in the targeting domain

Why the Bipartite Architecture Matters

The modular two-domain design of adipotide has broad implications beyond this specific compound. It serves as a conceptual template for targeted peptide therapy:

• •Targeting domain can be swapped for other homing sequences (RGD for tumor neovasculature, bombesin for prostate cancer, etc.)
• •Effector domain can be substituted with other cytotoxins, imaging agents, drug delivery payloads, or gene editing cargo
• •The GG linker provides flexible spacing; researchers have explored different linker lengths and cleavability
• •This design concept underlies a major field of oncology research ("vascular zip code" targeting) and peptide-drug conjugate development

---

Target: Prohibitin and Adipose Vasculature Selectivity

Prohibitin (PHB1/PHB2) is canonically known as a mitochondrial scaffold protein. Its discovery as a cell-surface receptor selectively displayed on adipose endothelium — but not on normal brain, heart, lung, or other vessel surfaces — was unexpected and represents one of the key contributions of vascular mapping studies using in vivo phage display.

Prohibitin Biology

PHB1 and PHB2 form a large ring complex (~2 MDa) in the inner mitochondrial membrane, where they function as scaffold proteins regulating mitochondrial dynamics, protein quality control, and electron transport chain assembly. PHB has also been identified at:

• •Plasma membrane (especially in adipose endothelial cells, as identified by adipotide targeting studies)
• •Nucleus (transcriptional corepressor)
• •Lipid rafts (signaling hub)

The translocation of PHB from mitochondria to the cell surface in adipose endothelium is not fully understood. Evidence suggests it involves:

• •Ceramide-dependent lipid raft reorganization in metabolically active adipose tissue
• •Elevated free fatty acid signaling in adipose microvascular beds
• •Obesity-dependent upregulation: PHB surface expression is higher in obese vs. lean animals, explaining the selectivity of adipotide's effects in obese models

PHB as a Research Target Beyond Adipotide

Prohibitin's role at the cell surface has implications beyond adipotide:

• •PHB1 surface expression on smooth muscle cells regulates vascular tone
• •PHB1 binds hepatitis C virus NS5A protein — PHB is being studied as an antiviral target
• •PHB2 (reprohibitin) surface expression on pancreatic cancer cells and tumor-associated vasculature — an active area of cancer biology

---

Preclinical Research Evidence

Murine Models

The seminal adipotide publication demonstrated that administration of CKGGRAKDC-GG-D(KLAKLAK)₂ to diet-induced obese mice produced approximately 30% weight reduction over 4 weeks, attributable to targeted apoptosis of white adipose tissue vasculature (PMID 20103704). Mechanistically:

• •Apoptosis was confirmed by TUNEL staining of adipose tissue sections showing selective endothelial cell death
• •Adipocyte necrosis followed vascular collapse, consistent with nutrient deprivation
• •Food intake was reduced, suggesting secondary metabolic effects (potentially mediated by adipokine changes following WAT remodeling)
• •Lean mice showed no significant weight change, supporting the obesity-dependent selectivity hypothesis
• •Subcutaneous and visceral fat depots were reduced; visceral fat reduction was particularly pronounced

Non-Human Primate Models

A critical translational study extended adipotide research to obese rhesus monkeys. MRI and DEXA imaging confirmed a marked, selective reduction in white adipose tissue mass following adipotide administration. Improved insulin sensitivity and fasting glucose normalization accompanied the fat loss in the NHP model — findings consistent with WAT reduction effects on systemic insulin resistance (PMC3666164).

Key NHP findings:

• •~11% body weight reduction over 28 days
• •Selective white fat loss (confirmed by MRI); lean mass preserved
• •Improved insulin sensitivity (IVGTT testing)
• •Renal toxicity (reversible changes in creatinine markers) noted at higher doses — an important safety signal for researchers designing dosing studies
• •No liver toxicity, hematological changes, or off-target organ pathology at therapeutic doses

The reversible renal toxicity at high doses was attributed to off-target prohibitin expression on kidney vasculature under high-dose conditions, suggesting a therapeutic window exists between efficacious and nephrotoxic doses.

Comparative Efficacy vs. Other Weight Loss Mechanisms

In preclinical models, adipotide's effects have been compared to semaglutide/GLP-1 agonists in some respects:

• •GLP-1 agonists primarily reduce appetite and slow gastric emptying; fat loss is gradual and requires sustained treatment
• •Adipotide directly destroys the vascular supply to WAT; effects are more rapid and mechanistically distinct
• •Adipotide preferentially reduces visceral and subcutaneous white fat without lean mass loss — a distinction from some caloric restriction or GLP-1 mediated weight loss that can include muscle catabolism
• •No GI side effects analogous to GLP-1 agonist nausea/vomiting have been reported in animal models

---

Obesity, Insulin Resistance, and the Adipose Vasculature

The Role of WAT Vascularization in Obesity

White adipose tissue is highly vascularized — each adipocyte is thought to be within 25–50 µm of a capillary. As adipose depots expand in obesity:

• •Adipose angiogenesis is required to support expansion (VEGF-A production by adipocytes drives vascular sprouting)
• •Hypoxic regions develop faster than vasculature can respond, creating inflammatory WAT
• •The adipose endothelium becomes a functional interface for inflammatory cell trafficking (monocyte adhesion, macrophage infiltration)
• •Endothelial dysfunction in adipose vasculature contributes to metabolic inflammation ("metaflammation")

Adipotide's targeting of this vasculature makes it a tool to study not just weight loss but the mechanistic role of adipose vascular supply in maintaining adiposity, adipose inflammation, and systemic metabolic function.

Adipokine Consequences of WAT Reduction

Following adipotide treatment in animal models, multiple adipokine shifts have been documented:

• •Leptin: Decreases proportionally to fat mass reduction
• •Adiponectin: Increases (adiponectin/leptin ratio improves) — consistent with improved insulin sensitivity
• •TNF-α: Decreases in WAT (consistent with reduced macrophage infiltration)
• •Resistin: Variable across models
• •These changes collectively improve systemic insulin sensitivity beyond what fat mass reduction alone predicts

Visceral vs. Subcutaneous Fat Selectivity

An important finding in adipotide research is the differential effect on fat depot types:

• •Visceral fat (mesenteric, omental) shows proportionally greater reduction than subcutaneous fat in some models
• •This is consistent with higher prohibitin surface expression in visceral adipose endothelium vs. subcutaneous
• •Visceral fat reduction has outsized metabolic benefits relative to subcutaneous fat reduction — making adipotide's depot specificity potentially advantageous vs. non-specific weight loss strategies

---

Cancer Biology Applications

Prohibitin Expression in Tumor Vasculature

Beyond obesity research, prohibitin targeting has implications in oncology:

• •PHB1/PHB2 are overexpressed in tumor-associated endothelium of multiple cancer types including breast, colorectal, and head/neck tumors
• •Adipotide-like constructs using CKGGRAKDC have been explored as antitumor agents in xenograft models
• •Combination with conventional chemotherapy agents has been tested in cell lines, showing potential synergistic cytotoxicity in PHB-overexpressing tumors

Targeted Drug Delivery via Prohibitin

The CKGGRAKDC homing peptide has been coupled to non-proapoptotic payloads:

• •Doxorubicin conjugates for targeted chemotherapy delivery
• •siRNA nanoparticles for adipose-selective gene silencing
• •Imaging agents for molecular imaging of adipose vasculature in metabolic disease models
• •Gold nanoparticles for photothermal therapy of fat deposits (experimental)

These applications demonstrate that CKGGRAKDC functions as a versatile targeting vector beyond adipotide's original design.

---

Research Applications

Primary Research Uses

• •Adipose biology: Studying WAT vascularization, angiogenesis dependence, and adipocyte-endothelial cell signaling
• •Prohibitin surface biology: Characterizing adipose endothelium-specific prohibitin display and its regulation by metabolic state
• •Targeted apoptosis methodology: Using adipotide as a model system for receptor-targeted proapoptotic peptide design
• •Obesity mechanism research: Studying consequences of selective WAT devascularization on systemic metabolism, adipokine profiles, and glucose homeostasis
• •Cancer biology crossover: Prohibitin targeting has implications for tumor vasculature research (PHB expression in tumor-associated vessels)
• •Drug conjugate platform: CKGGRAKDC as a homing vector for diverse payloads

Relationship to Other Vascular-Targeted Research Peptides

Adipotide belongs to a broader research category of "vascular zip code"-targeted compounds pioneered by the Arap-Pasqualini laboratory at MD Anderson. The same phage display approach identified other organ-specific homing peptides targeting brain, lung, and kidney vasculature — making adipotide a tractable model for the wider field of vascular address targeting.

Other notable compounds from the same research lineage:

• •CGKRK: A brain vasculature-homing peptide
• •CRGDKGPDC: Integrin-homing peptide for angiogenic vasculature
• •Lyp-1: A lymphatic vessel/lymph node tumor homing peptide targeting p32
• •F3: A nucleolin-targeting peptide for tumor vasculature

---

Molecular Design Principles for Research Context

Adipotide's design exemplifies several concepts relevant to targeted peptide research:

Bipartite modular design: Separable targeting and effector domains connected by a cleavable or stable linker is a general strategy for tumor-targeted, organ-specific, or cell-type-specific peptide constructs. Researchers studying similar approaches can use adipotide as a structural template.

D-amino acid enantiomers for protease resistance: The D(KLAKLAK)₂ domain uses D-amino acids throughout — a strategy that dramatically extends in vivo half-life without altering the gross amphipathic helical structure required for membrane disruption. This principle is broadly applicable in therapeutic peptide design research.

Disulfide-stabilized targeting sequences: The CKGGRAKDC homing motif contains cysteines that form an intramolecular disulfide bond — a structural feature critical for the correct PHB-binding conformation. Research protocols should verify disulfide bond status in received material.

Amphipathic membrane disruption: The (KLAKLAK)₂ sequence forms a cationic amphipathic helix that binds negatively charged mitochondrial membranes and disrupts their bilayer structure. This lytic mechanism is distinct from pore-forming toxins and is specific to negatively charged membranes (which inner mitochondrial membranes are, unlike most plasma membranes). This selectivity for mitochondria vs. cell surface is critical to the compound's function — without the CKGGRAKDC targeting domain, D(KLAKLAK)₂ alone cannot efficiently reach mitochondria.

---

Research Protocol Considerations

Reconstitution

• •Dissolve lyophilized adipotide in sterile 0.9% NaCl or PBS
• •Target concentration: 10–100 µM working solution
• •Sonication (water bath, 5–10 min) may aid dissolution of this larger peptide
• •Avoid vortexing; gentle mixing or inversion preferred

Verifying Disulfide Bond Status

Because the CKGGRAKDC domain depends on an intramolecular disulfide bond for correct PHB binding, verify material quality with:

• •Ellman's reagent (DTNB assay): Low free thiol signal indicates intact disulfide
• •Mass spectrometry: [M-2H] mass shift confirms S-S bond formation
• •Circular dichroism: Can verify secondary structure of the targeting domain in solution

Dosing in Rodent Models

Based on published protocols:

• •Lean control animals: 200–400 µg/kg/day SC for 28 days (typically ineffective — use as control)
• •Diet-induced obese (DIO) mice: 200–400 µg/kg/day SC; significant fat loss at day 14–28
• •NHP: Lower effective doses (~50–100 µg/kg); monitor renal function markers weekly
• •Always include bodyweight-matched lean controls to confirm obesity-dependent selectivity

Storage and Stability

• •Lyophilized: Stable at -20°C for ≥2 years when desiccated
• •Avoid repeated freeze-thaw cycles (>3 cycles may compromise disulfide integrity)
• •Reconstituted: Use within 24–48 hours; do not store >4°C if possible
• •Protect from light (amber tubes recommended for long-term storage)

---

Adipotide Pricing: Research Supplier Landscape (2026)

Adipotide is available from several verified research suppliers. Pricing reflects custom synthesis costs given the compound's structural complexity (D-amino acid content, disulfide bond requirement):

Pricing reflects current listings. Adipotide synthesis complexity means price variation reflects purity and D-amino acid quality. Always verify mass spec confirmation and HPLC ≥95% purity. View live pricing at Peptides.SO.

What to look for in research-grade Adipotide:

• •HPLC chromatogram showing single peak ≥95% purity
• •Mass spectrometry report confirming molecular weight ~2,800 Da with [M-2H] shift confirming disulfide formation
• •Certificate of Analysis with lot-specific testing
• •D-amino acid content verification (some suppliers use L-amino acid KLAKLAK for cost reduction, which dramatically reduces efficacy)

---

Comparison to Other Anti-Obesity Research Compounds

Adipotide is unique in directly destroying the vascular supply to fat rather than reducing energy intake or increasing fat mobilization. This mechanism makes it a highly valuable research tool for studying WAT vascular biology even if its clinical development is uncertain.

---

2024–2026 Research Context

GLP-1 Agonist Explosion and Adipotide Relevance

The approval of semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) has dramatically shifted the obesity research landscape. In this context, adipotide remains scientifically interesting because:

1. Mechanism distinction: Adipotide's vascular apoptosis approach is entirely distinct from GLP-1 signaling — valuable for combination studies

2. Rebound resistance hypothesis: GLP-1 agonist weight loss rebounds upon discontinuation; adipotide-mediated fat reduction (via vascular destruction) may be more durable

3. Visceral fat targeting: Adipotide's visceral fat selectivity could complement GLP-1 agents that reduce overall body fat without depot specificity

Prohibitin Biology Resurgence

New structural studies (2022–2025) using cryo-EM have refined understanding of the PHB1/PHB2 complex architecture, revealing:

• •Tissue-specific PHB complex compositions (different PHB1/PHB2 stoichiometry in mitochondria vs. cell surface)
• •Role of PHB in mitophagy regulation — PHB-deficient cells show impaired mitophagy
• •PHB2 as a cardiolipin sensor that coordinates mitochondrial membrane remodeling during fission

These structural insights help explain WHY PHB1 is accessible on adipose endothelial cell surfaces and are driving new PHB-targeted drug design approaches.

Adipotide as a Research Tool for Fibrosis Models

Recent studies have used adipotide to selectively deplete perivascular adipose tissue (PVAT) in vascular biology models, studying:

• •How PVAT influences vascular inflammation and plaque development in atherosclerosis
• •PVAT contribution to vascular stiffness
• •Adipocyte-derived factors that modulate smooth muscle cell function in the vessel wall

---

Frequently Asked Questions

Q: Has adipotide been tested in humans?

A: No completed human trials have been published. The NHP data from obese rhesus monkeys (with documented efficacy and a manageable safety profile) represents the most advanced preclinical data. The reversible renal toxicity at high doses in NHPs was identified as a key hurdle for clinical development.

Q: Why doesn't adipotide affect normal-weight animals?

A: The selectivity depends on obesity-associated upregulation of prohibitin surface expression on white adipose endothelium. In lean animals, PHB surface expression on WAT vasculature is lower, reducing adipotide's binding and uptake. This creates a biologically built-in safety mechanism — adipotide selectively targets pathological fat depots.

Q: How does adipotide compare to liposuction?

A: Liposuction physically removes adipocytes; adipotide destroys the vascular supply causing subsequent adipocyte death. Adipotide affects both subcutaneous and visceral fat, while liposuction only targets accessible subcutaneous depots. Adipotide's effects also include metabolic improvements (insulin sensitivity) that purely mechanical fat removal does not produce.

Q: What is the relationship between adipotide and retatrutide?

A: They represent fundamentally different approaches. Retatrutide is an injectable hormonal agonist (GIP/GLP-1/glucagon receptor) that achieves 24% weight loss through appetite suppression and metabolic regulation. Adipotide is a targeted proapoptotic peptide that destroys fat-feeding vasculature. Both are active research areas with distinct mechanisms, risks, and potential applications.

Q: What is the D(KLAKLAK)₂ domain's selectivity for mitochondria vs. cell membrane?

A: The selectivity is largely charge-based. Mitochondrial inner membranes carry a highly negative surface charge (cardiolipin-rich). Plasma membranes of mammalian cells are predominantly neutral (phosphatidylcholine/phosphatidylethanolamine outer leaflet). D(KLAKLAK)₂ selectively inserts into negatively charged bilayers — meaning it disrupts mitochondria far more efficiently than cell surface membranes. This selectivity means that reaching mitochondria (intracellularly, after endocytosis via PHB binding) is necessary for apoptosis induction.

---

Related Research Articles

• •TB-500 (Thymosin Beta-4) Research Guide 2026: Healing, Recovery, and Cost Analysis
• •BPC-157 vs TB-500: Which Healing Peptide Is Better for Research?
• •Retatrutide (LY3437943): Triple Hormone Receptor Agonist — Complete Research Profile
• •Peptide Purity Testing Methods: HPLC and Mass Spectrometry Explained

---

Conclusion

Adipotide represents one of the most intellectually creative peptide research compounds in the obesity and metabolic disease field. Its bipartite design — combining a prohibitin-targeting homing peptide with a mitochondria-disrupting proapoptotic effector — produces the specific, anatomy-guided destruction of white adipose tissue vasculature with remarkable selectivity.

The preclinical evidence is compelling: 30% fat mass reduction in obese mice with metabolic normalization, and validated translation to obese non-human primates with preserved lean mass and improved insulin sensitivity. The identified renal safety signal at high doses provides a defined path for dosing optimization in future studies.

For researchers, adipotide offers value as:

1. A tool to study adipose vascular biology and WAT physiology

2. A template for bipartite targeted peptide design

3. A prohibitin-targeting vector for drug/imaging payload delivery

4. A mechanistic comparison point for GLP-1 vs. vascular-targeted obesity interventions

In the context of the current obesity treatment revolution driven by GLP-1 agonists, adipotide's distinct mechanism positions it as a potentially synergistic partner or mechanistic alternative — particularly for visceral fat targeting and durable fat mass reduction.

Research Use Only. Adipotide/FTPP is sold for research purposes only. Not for human consumption or veterinary use without appropriate professional supervision. Consult applicable regulations before use.